NCT06427668View on ClinicalTrials.gov

Study of SPG302 in Adult Participants With Mild-to-Moderate Alzheimer's Disease (AD)

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

July 29, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions

Alzheimer Disease

Interventions

DRUG

SPG302

synthetic small molecule

DRUG

Placebo

Placebo

Trial Locations (2)

2010

St Vincent's Hospital, Sydney

5000

Flinders Medical center, Adelaide

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Spinogenix

INDUSTRY